Donna M. Ballantine
University of Queensland
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Donna M. Ballantine.
Clinical and Experimental Pharmacology and Physiology | 1995
Shelley A. Klemm; Donna M. Ballantine; Terry J. Tunny; Michael Stowasser; Richard D. Gordon
1. In patients with primary aldosteronism due to angiotensin‐responsive and andotensin‐unresponsive aldosterone‐producing adenomas, no differences in the coding region of the angiotensin II type 1 (AT1) receptor gene were observed compared to normal subjects in peripheral blood leucocyte DNA.
Clinical and Experimental Pharmacology and Physiology | 1996
Donna M. Ballantine; Shelley A. Klemm; Terry J. Tunny; Michael Stowasser; Richard D. Gordon
1. Mutations of the p53 tumour suppressor gene are relatively common in the aetiology of a wide spectrum of tumour types, both sporadic and familial.
Clinical and Experimental Pharmacology and Physiology | 1994
Donna M. Ballantine; Shelley A. Klemm; Terry J. Tunny; Michael Stowasser; Richard D. Gordon
1. Aldosterone levels in patients with unilateral aldosterone‐producing adenomas may be responsive or unresponsive to the renin‐angiotensin system, with the former often previously misdiagnosed as bilateral adrenal hyperplasia.
Clinical and Experimental Pharmacology and Physiology | 1993
Anthony W. Bachmann; Donna M. Ballantine; Richard D. Gordon
1. The effects of 6 h infusions of adrenaline (INF‐A) or dextrose (INF‐D) and of post‐infusion cold pressor test (CPT) were compared in normal subjects, with (FH +) and without (FH ‐) a family history of hypertension.
Clinical and Experimental Pharmacology and Physiology | 1992
Richard D. Gordon; Donna M. Ballantine; Anthony W. Bachmann
1. Increases in blood pressure (BP) and in plasma noradrenaline concentration (NA) were observed after two doses of a non‐prescription decongestant containing pseudoephedrine (PE) in two of three patients with phaeochromocytoma, before but not after removal of the tumour. The pressor response was terminated by oral phenoxybenzamine, and modified by prior exposure to this drug.
Clinical and Experimental Pharmacology and Physiology | 1996
Donna M. Ballantine; Shelley A. Klemm; Terry J. Tunny; Michael Stowasser; Richard D. Gordon
Aldosterone‐producing adenomas (APA) of the adrenal gland may be responsive or un‐responsive to the renin‐angiotensin system.
Clinical and Experimental Pharmacology and Physiology | 1995
Donna M. Ballantine; Shelley A. Klemm; Terry J. Tunny; Michael Stowasser; Richard D. Gordon
1. Angiotensin‐responsive aldosterone‐producing adenomas (AII‐R‐APA) have increased expression of renin mRNA compared with angiotensin‐unresponsive aldosterone‐producing adenomas (AII‐U‐APA) or normal adrenals.
Clinical and Experimental Pharmacology and Physiology | 1991
Richard D. Gordon; Anthony W. Bachmann; Donna M. Ballantine; Robyn E. Thompson
1. Significant increases in arterial noradrenaline (NA) of similar magnitude were seen in normotensive (NT) and hypertensive humans (HT) during adrenaline (ADR) infusion.
Clinical and Experimental Pharmacology and Physiology | 1992
Anthony W. Bachmann; Richard D. Gordon; Donna M. Ballantine
1. The effects of 6 h infusions of adrenaline (INF‐A) and dextrose (INF‐D) were compared in nine normal subjects.
Biochemical and Biophysical Research Communications | 1994
Terry J. Tunny; J.R. Jonsson; Shelley A. Klemm; Donna M. Ballantine; Michael Stowasser; Richard D. Gordon